The last 10 days of patients with glioblastoma: Assessment of clini- cal signs and symptoms as well as treatment. Am J Hosp Palliat Care. 2016;33:985--8.Their, K.; Calabek, B.; Tinchon, A.; Grisold, W.; Oberndorfer, S. The last 10 days of patients with glioblas- toma: ...
The Last 10 Days of Patients With Glioblastoma: Assessment of Clinical Signs and Symptoms as well as Treatment The last 10 days of patients with glioblastoma: assessment of clinical signs and symptoms as well as treatment. Am J Hosp Palliat Care. doi: ... Oberndorfer,Stefan,Calabek,... -...
[22] have investigated 33 patients who completed questionnaires before starting PBT, on last day of treatment, and at every follow-up visit until disease progression. It appears that PBT is safe and well tolerated, ensuring stable quality-of-life parameters for the duration. The Proton ...
By interrogating single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic profiles of GBM patient tumors, we confirm that the identified Mg states in PDOXs are also abundant in patients and localize variably across spatial TME niches. Notably, high proportions of these Mg-TAMs present ...
This system led to a better discrimination of outcome for patients who underwent treatment at the Mayo Clinic than did the Kernohan system. The most widely used system today for classification of astrocytomas is part of the WHO classification of tumors of the CNS, which was last updated in ...
Glioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into bet
The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to repo
“all-comer” clinical trials where drug agents result in less than 50% response in patients [83]. The concept of precision medicine provides a potential avenue, where patient-specific abnormalities are identified using next generation omics approaches, and drug agents targeting these aberrations, if...
We observed an increase in the relative proportion of monocytic-lineage cells from the periphery at recurrence (Fig.5a). We and others have shown that the abundances of myeloid-derived cells from peripheral blood and MES neoplastic cells correlate across patients and that these cell types co-occup...
MDSCs and TAMs MDSCs and TAMs are a heterogeneous population of immature myeloid cells, that are located in the tumor tissue and the peripheral blood of patients with glioma. Although TAMs and MDSCs are considered separate entities, the boundaries between them are not clearly delimited and they...